Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $492.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −11 vs. previous quarter
- 161
- 13F valueReported value at the end of Q2 2026
- $782.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $175.1M
- +216.9% year over year
- Net income, FY2025
- -$221.2M
- No comparable prior period
- Free cash flow, FY2025
- -$167.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $84.7M
- +71.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $221.2M (126.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 9.20M
- Shares sold short
- Change
- −580.1K
- −5.9% vs. previous
- Days to cover
- 4.83
- At average daily volume
Superinvestors holding PHAT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PHAT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Phathom Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2025 (view filing) | Nov 3 | 2 days | Breedlove Robert CharlesPrincipal Accounting Officer | SSale | −524 | $13.51 | −$7.08K | −1.1%47.4K after | |
| Sep 9, 2025 (view filing) | Sep 5 | 4 days | Breedlove Robert CharlesPrincipal Accounting Officer | SSale | −461 | $12.09 | −$5.57K | −1.0%47.9K after | |
| Jul 18, 2025 (view filing) | Jul 16 | 2 days | Breedlove Robert CharlesPrincipal Accounting Officer | SSale | −1.69K | $8.36 | −$14.1K | −3.4%48.4K after | |
| May 23, 2025 (view filing) | May 21 | 2 days | Topper James NDirector | PPurchase | +3.78K | $3.86 | +$14.6K | +6.8%59.4K after | |
| May 15, 2025 (view filing) | May 13-14 | 2 days | Topper James NDirector | PPurchase | +7.42K | $3.30 | +$24.5K | +15.4%55.6K after | 2 lots |
| May 13, 2025 (view filing) | May 9-12 | 4 days | Topper James NDirector | PPurchase | +48.2K | $3.17 | +$152.8K | New position48.2K after | 3 lots |
| May 8, 2025 (view filing) | May 6-7 | 2 days | Parikh AsitDirector | PPurchase | +10.0K | $2.50 | +$25.0K | +11.7%95.5K after | 2 lots |
| Apr 8, 2025 (view filing) | Apr 7 | 1 day | Henderson MollyCFO and CBO | SSale | −3.68K | $4.55 | −$16.7K | −3.9%89.9K after | |
| Mar 17, 2025 (view filing) | Mar 13 | 4 days | Parikh AsitDirector | PPurchase | +10.0K | $4.42 | +$44.2K | +13.2%85.5K after | |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Henderson MollyCFO and CBO | SSale | −6.58K | $6.59 | −$43.4K | −6.6%93.5K after |
Top 10 13F holders, Q2 2026
See all 161 holdersThe largest institutional positions in Phathom Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12,466,489 | $135.3M | 2.95% | 00.0% | Unchanged |
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | $81.0M | 45.65% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,525,129 | $49.1M | 0.00% | +463,133+11.4% | Added |
| Invesco Ltd. | 4,029,731 | $43.7M | 0.00% | −292,329−6.8% | Reduced |
| Carlyle Group Inc. | 3,496,808 | $37.9M | 0.38% | 00.0% | Unchanged |
| Millennium Management LLC | 3,375,834 | $36.6M | 0.02% | −647,075−16.1% | Reduced |
| Vanguard Capital Management LLC | 2,656,944 | $28.8M | 0.00% | +73,308+2.8% | Added |
| GW&K Investment Management, LLC | 2,166,838 | $23.5M | 0.18% | +745,729+52.5% | Added |
| Franklin Resources Inc | 1,970,828 | $21.4M | 0.00% | +976,324+98.2% | Added |
| NEA Management Company, LLC | 1,960,169 | $21.3M | 1.34% | 00.0% | Unchanged |
Holders of 5% or more of PHAT
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Phathom Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 13D/A | 7.40%6.01M shares | −1.20 ppfrom 8.60% | May 5, 20238 filings | Nov 2, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.50%4.38M shares | +0.90 ppfrom 4.60% | Oct 21, 20244 filings | Jul 29, 2026 | SEC |